Success Metrics

Clinical Success Rate
25.0%

Based on 1 completed trials

Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
400%(4 trials)
Terminated
3(75%)

Phase Distribution

Ph phase_3
4
100%

Phase Distribution

0

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution4 total trials
Phase 3Large-scale testing
4(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(3)

Detailed Status

Terminated3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 3

Trials by Phase

Phase 34 (100.0%)

Trials by Status

completed125%
terminated375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

NCT03353350
terminatedphase_3

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

NCT03770728
terminatedphase_3

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

NCT03713684
terminatedphase_3

Effect of Efpeglenatide on Cardiovascular Outcomes

NCT03496298

Clinical Trials (4)

Showing 4 of 4 trials
NCT03353350Phase 3

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Completed
NCT03770728Phase 3

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

Terminated
NCT03713684Phase 3

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Terminated
NCT03496298Phase 3

Effect of Efpeglenatide on Cardiovascular Outcomes

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4